Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INXN-4001

Gene therapy

Phase 1 Most advanced trial (none active)
1 Registered trials

What is INXN-4001?

INXN-4001 is a triple effector plasmid delivered by retrograde coronary sinus infusion. It is studied in heart failure and cardiovascular diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy
Therapy area
Cardiovascular
In trials of
PGEN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03409627 Phase 1 Heart Failure Completed PGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cardiovascular DiseasesHeart FailureHeart-Assist Device

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.